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ABSTRACT
  
TITLE: Targeting Transforming Growth Factor beta 2 (TGF-β2) mRNA with ISTH0036 as Novel Therapeutic
Intervention in Neovascular Ocular Disease
ABSTRACT BODY: 
Purpose: Although anti-VEGF therapeutics represent a significant step forward in treating neovascular eye diseases,
insufficient response to anti-VEGF-treatments represents a significant clinical problem. Therefore, novel therapies with
alternative molecular mechanisms of action are desirable. We recently reported potent activity of ISTH0036, a LNA-
modified antisense oligonucleotide specifically targeting the sequence of TGF-β2 mRNA, in a murine glaucoma
filtration surgery model. The aim of the present studies was to evaluate the therapeutic potential of ISTH0036 in a
murine model of laser-induced choroidal neovascularization (CNV).
Methods: Effect of ISTH0036 on TGF-β2 mRNA expression and cell migration was explored on murine astrocytes to
ensure target engagement and pharmacological effect in these cells. The posterior eye tissue distribution was
determined following intravitreal (IVT) injection of DIG-labeled ISTH0036. Subsequently, the effect of the drug was
studied in a murine CNV model by performing 3 laser-induced burns on the Bruch’s membrane of the eyes (n= 5-9
mice/group). IVT injections of test items were performed directly after laser treatment. Experimental outcomes
included inflammation (CD45 staining, on day 5), presence of CNV pathology (FA and OCT, on days 5-14),
angiogenesis (FITC-dextran staining, on day 14), and fibrotic processes (collagen I deposition, on day 28).
Results: ISTH0036 showed potent downregulation of target mRNA and inhibition of migration of murine astrocytes in
cell based assays. ISTH0036 was detectable in most of the tested posterior eye tissues; including sclera, retina,
choroid and ciliary body. In the murine CNV model, ISTH0036 was shown to significantly reduce the process of
angiogenesis in a dose-and sequence-dependent manner. Beneficial inhibitory effect of ISTH0036 on the progression
of CNV pathology and vascular leakage was demonstrated. In addition, and in contrast to existing anti-VEGF
treatments, deposition of collagen was significantly reduced with ISTH0036.
Conclusions: Our results confirm that targeting TGF-β2 in CNV may represent an attractive modality for the effective
treatment of neovascular ocular diseases such as wet AMD and diabetic retinopathy. Demonstrated potent inhibitory
effects on vascular leakage, angiogenesis and fibrosis support further clinical development of ISTH0036 in these
relevant indications.
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